{"title":"Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?","authors":"","doi":"10.1016/j.cllc.2024.06.003","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>After osimertinib<span> resistance some patients are still sensitive to EGFR blockage.</span></p></span></li><li><span>•</span><span><p>Gefitinib rechallenge seems effective after a TKI-free interval.</p></span></li><li><span>•</span><span><p><span>Liquid biopsy can track clonal evolution of </span><em>EGFR</em> mutated NSCLCs.</p></span></li><li><span>•</span><span><p>Detection of EGFR mutations on ctDNA can identify patients for this strategy.</p></span></li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 6","pages":"Pages e262-e267"},"PeriodicalIF":3.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424001128","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
•
After osimertinib resistance some patients are still sensitive to EGFR blockage.
•
Gefitinib rechallenge seems effective after a TKI-free interval.
•
Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.
•
Detection of EGFR mutations on ctDNA can identify patients for this strategy.
期刊介绍：
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
